Exposure to Total and Protein-Unbound Rifampin Is Not Affected by Malnutrition in Indonesian Tuberculosis Patients

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2015-03-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1128/AAC.03485-14PMID 25801554PMCID PMC4432135
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Unbound fraction of vancomycin in intensive care unit patients

  2014cited by this paper
• Determination of free vancomycin, ceftriaxone, cefazolin and ertapenem in plasma by ultrafiltration: impact of experimental conditions.

  2014cited by this paper
• Low rifampicin concentrations in tuberculosis patients with HIV infection.

  2014cited by this paper
• Factors Associated with Variability in Rifampin Plasma Pharmacokinetics and the Relationship between Rifampin Concentrations and Induction of Efavirenz Clearance

  2014cited by this paper
• Isoniazid, Rifampin, and Pyrazinamide Plasma Concentrations in Relation to Treatment Response in Indonesian Pulmonary Tuberculosis Patients

  2013cited by this paper
• Interaction of Nutrition and Infections Globally: An Overview

  2013cited by this paper
• Serum drug concentrations predictive of pulmonary tuberculosis outcomes.

  2013cited by this paper
• Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.

  2012cited by this paper
• Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake

  2011cited by this paper
• The SLCO1B1 rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications

  2011cited by this paper
• Protein Binding: Do We Ever Learn?

  2011cited by this paper
• Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.

  2011cited by this paper
• Effects of Tuberculosis, Race, and Human Gene SLCO1B1 Polymorphisms on Rifampin Concentrations

  2010cited by this paper
• Significance of protein binding in pharmacokinetics and pharmacodynamics.

  2010cited by this paper
• A systematic review of pharmacokinetics studies in children with protein-energy malnutrition

  2010cited by this paper
• Pharmacokinetics of Antituberculosis Drugs in Pulmonary Tuberculosis Patients with Type 2 Diabetes

  2009cited by this paper
• Malnutrition and socio-demographic factors associated with pulmonary tuberculosis in Timor and Rote Islands, Indonesia.

  2009cited by this paper
• Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.

  2009cited by this paper
• PK/PD: new insights for antibacterial and antiviral applications.

  2008cited by this paper
• Peak plasma rifampicin level in tuberculosis patients with slow culture conversion

  2008cited by this paper
• Pharmacokinetics and Tolerability of a Higher Rifampin Dose versus the Standard Dose in Pulmonary Tuberculosis Patients

  2007influential reference
• Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management.

  2007cited by this paper
• Determinants of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol Pharmacokinetics in a Cohort of Tuberculosis Patients

  2006cited by this paper
• Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes.

  2006cited by this paper
• Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.

  2005cited by this paper
• Stability, pKa and plasma protein binding of roscovitine.

  2005cited by this paper
• Bioavailability of rifampicin in Indonesian subjects: a comparison of different local drug manufacturers.

  2004cited by this paper
• Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid

  2003cited by this paper
• Pharmacokinetic Interactions with Rifampicin

  2003cited by this paper
• Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine.

  2003cited by this paper
• Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia.

  2002cited by this paper
• Changes in plasma protein binding have little clinical relevance

  2002cited by this paper
• The albumin-nutrition connection: separating myth from fact.

  2002cited by this paper
• Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy.

  2001cited by this paper
• Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors.

  2001cited by this paper
• Malnutrition in tuberculosis.

  1999cited by this paper
• Malnutrition: Organic and Functional Consequences

  1999cited by this paper
• Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients.

  1998cited by this paper
• Influence of Diet and Nutritional Status on Drug Metabolism

  1996cited by this paper
• Rifampicin kinetics in undernutrition.

  1984cited by this paper
• Metabolism and pharmacokinetics of the antibiotic rifampin.

  1981influential reference
• Sex difference in blood levels of some antibiotics.

  1973cited by this paper

• Rifampicin concentrations throughout the entire treatment duration of active tuberculosis; impact of sex and body mass index.

  2025cites this paper
• Protein binding investigation of first-line and second-line antituberculosis drugs.

  2023cites this paper
• Drug transdermal delivery by electrophonophoresis can increase the concentration of rifampicin in the pleural effusion of patients with tuberculous pleurisy but has no effect on the concentration of rifampicin in plasma.

  2023cites this paper
• Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis

  2022cites this paper
• Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fiber system that simulates human plasma and epithelial lining fluid pharmacokinetics.

  2021cites this paper
• Malnutrition assessment methods in adult patients with tuberculosis: a systematic review

  2021cites this paper
• Determination of Free Valproic Acid Concentration in 569 Clinical Samples by LC-MS/MS After Hollow Fiber Centrifugal Ultrafiltration Treatment

  2021cites this paper
• Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review

  2021cites this paper
• Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg−1 rifampicin

  2021cites this paper
• Drug-Nutrition Interactions in Infectious Diseases

  2020cites this paper
• Therapeutic drug monitoring of rifampicin, isoniazid, and pyrazinamide in newly-diagnosed pulmonary tuberculosis outpatients in Denpasar area

  2019cites this paper
• A Pharmacology Perspective on Simultaneous Tuberculosis and Hepatitis C Treatment

  2019cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis

  2019cites this paper
• Clinical Significance of the Plasma Protein Binding of Rifampicin in the Treatment of Tuberculosis Patients

  2019cites this paper
• A double-blinded randomised placebo-controlled phase II trial to evaluate high dose rifampicin for tuberculous 1 meningitis : a dose finding study 2

  2018cites this paper
• Caution when treating tuberculosis in malnourished children

  2018cites this paper
• Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for Tuberculous Meningitis

  2018cites this paper
• Clinical pharmacokinetics of drugs in cardiopulmonary associated cachexia without hepatorenal pathology: a systematic review

  2018influential citation
• Protein binding of rifampicin is not saturated when using high-dose rifampicin

  2018cites this paper
• Disease-related malnutrition and nutritional assessment in clinical practice

  2018cites this paper
• A double-blinded randomised placebo-controlled phase II trial to evaluate high dose rifampicin for tuberculous meningitis: a dose finding study

  2018cites this paper
• Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria

  2018cites this paper
• Protein Binding of First-Line Antituberculosis Drugs

  2018cites this paper
• Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide

  2017cites this paper
• University of Groningen Clinical pharmacology and therapeutic drug monitoring of first-line anti-tuberculosis drugs

  2017cites this paper
• Determination of protein-unbound, active rifampicin in serum by ultrafiltration and Ultra Performance Liquid Chromatography with UV detection. A method suitable for standard and high doses of rifampicin.

  2017cites this paper
• DOSING OF ANTI-TUBERCULOSIS DRUGS POORLY PREDICTS DRUG EXPOSURE IN TB PATIENTS WITH EXTENSIVE DISEASE

  2016cites this paper
• Malnutrition et carences des micronutriments chez les enfants

  2016cites this paper
• Clinical pharmacology and therapeutic drug monitoring of first-line anti-tuberculosis drugs

  2016cites this paper
• Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis

  2015cites this paper